B700 Antigen as a Component of an Antimelanoma Vaccine: Formalinized Extracellular Antigens

Pigment Cell Research

Volumn 5, Issue 3, 1992, Pages 107-112

  SHRAYER, DAVID ^a   GERSTEN, DOUGLAS M ^b   KONESS, JAMES ^a   MAIZEL, ABBY ^a   WANEBO, HAROLD ^a   HEARING, VINCENT J ^c  

^a BROWN UNIVERSITY   (United States)

^b GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Antibodies; Antigens; Melanoma; Vaccination

Indexed keywords

FORMALDEHYDE; MELANOMA SPECIFIC ANTIGENS; MELANOMA-SPECIFIC ANTIGENS; TUMOR PROTEIN; VACCINE;

ANIMAL; ARTICLE; C57BL MOUSE; CELL CULTURE; CHEMISTRY; CULTURE MEDIUM; FEMALE; GERMFREE ANIMAL; IMMUNOLOGY; MELANOMA; MOUSE;

ANIMALS; CULTURE MEDIA, CONDITIONED; FEMALE; FORMALDEHYDE; MELANOMA; MICE; MICE, INBRED C57BL; NEOPLASM PROTEINS; SPECIFIC PATHOGEN-FREE ORGANISMS; TUMOR CELLS, CULTURED; VACCINES;

EID: 0026912625     PISSN: 08935785     EISSN: 16000749     Source Type: Journal    
DOI: 10.1111/j.1600-0749.1992.tb00006.x     Document Type: Article

References (20)

1. Treatment of metastatic melanoma with an autologous tumor cell vaccine: clinical and immunologic results in 64 patients
2. Immunogenicity of a polyvalent melanoma antigen vaccine in humans
3. Production of monoclonal antibodies against the B700 murine melanoma antigen and their antimetastatic properties
4. The intracellular association of B700 and B50 murine melanoma antigens and their role in tumor rejection
5. Demonstration of B700 cross‐reactive antigens on human and other animal melanomas
6. Abnormal protein synthesis in malignant melanoma cells
7. Murine melanoma‐specific tumor rejection activity elicited by a purified melanoma‐associated antigen
8. Formalinized extracellular antigens of B16 melanoma are effective antitumor vaccines
9. Cleavage of structural proteins during the assembly of the head of bacteriophage T4
10. 2 antibodies in melanoma patients
11. 2 ganglioside
12. Histopathology of salivary and mammary gland tumors in transgenic mice expressing a human Ha‐ras oncogene
13. Melanoma tumor vaccine: five year follow‐up
14. Active specific immunotherapy for melanoma
15. Chemical crosslinking: reagents and problems in studies of membrane structure
16. 3 recognized by antibodies in melanoma patients after active specific immunotherapy
17. Chemical events in immune induction: evidence for a covalent intercellular reaction essential in antigen‐specific T cell activation
18. Melanoma patient antibody responses to melanoma tumor‐associated antigens defined by murine monoclonal antibodies
19. Prevention of tumor growth and metastasis of B16 melanoma with formalinized extracellular antigen (FECA) vaccination